EUVIMEDEUVIMED entdecken
Crossref

Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes

Yingnan Fan iD, Baoqi Fan, Eric S H Lau, Cadmon K P Lim, Hongjiang Wu, Edith W K Chow, Alice P S Kong, Elaine Chow, Ronald C W Ma, Juliana C N Chan, Andrea O Y Luk

Diabetes/Metabolism Research and Reviews · 2026

DOI: 10.1002/dmrr.70126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Yingnan Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, C-Peptide, Insulin-Secreting Cells, Insulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Hong Kong Government Health and Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aims to evaluate the predictive performance of clinical characteristics and beta‐cell function markers for future insulin requirements in Chinese individuals with type 2 diabetes who were not insulin deficient. Materials and Methods A prospective cohort of 2421 individuals with type 2 diabetes and fasting plasma C‐peptide ≥ 0.25 nmol/L (1996–2012) was followed until 2019 for insulin requirement, defined as insulin initiation or two consecutive HbA1c ≥ 8.5% while on at least two non‐insulin glucose‐lowering drugs. Cox regression with stepwise selection was used to identify predictors and derive a clinical risk score. Model calibration was assessed using the Hosmer‐Lemeshow test, and discrimination using the Harrell's C‐index and area under the receiver operating characteristic curve (AUC) at one, five and 10 years.

Results

Over a median follow‐up of 10.2 (IQR 4.0–14.1) years, 1143 individuals progressed to insulin requirements. Younger age at diabetes diagnosis, male sex, poorer glycaemic control, kidney complications and greater use of non‐insulin glucose‐lowering drugs were identified as independent predictors. The clinical risk score demonstrated better discrimination (C‐index: 0.729, AUCs: 0.829 at 1 year, 0.792 at 5 years, 0.779 at 10 years) than fasting plasma C‐peptide (C‐index: 0.532, AUCs: 0.502, 0.553, 0.537), C‐peptide‐to‐glucose ratio (C‐index: 0.560, AUCs: 0.660, 0.572, 0.571) and HOMA2‐%B (C‐index: 0.618, AUCs: 0.734, 0.651, 0.639) (all p < 0.001). Adding fasting plasma C‐peptide or HOMA2‐%B to the clinical model did not significantly improve its predictive performance.

Conclusions

Clinical characteristics outperformed fasting beta‐cell function markers in predicting insulin requirements in non‐insulin‐deficient type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2C-PeptideInsulin-Secreting CellsInsulinBiomarkersFastingHypoglycemic AgentsHumansMaleProspective StudiesFemaleMiddle AgedPrognosisFollow-Up StudiesBlood GlucoseRisk FactorsGlycated Hemoglobin

Stichwörter der Autor:innen

beta‐cell functionfasting plasma c‐peptideinsulin therapy requirementtype 2 diabetes

Substanzen

C-PeptideInsulinBiomarkersHypoglycemic AgentsBlood GlucoseGlycated Hemoglobin

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
  • Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
  • Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.

ORCID-Profile: Yingnan Fan

Förderung

  • Hong Kong Government Health and Medical Research Fund

Zitieren

APA

Fan, Y., Fan, B., Lau, E. S. H., Lim, C. K. P., Wu, H., Chow, E. W. K., Kong, A. P. S., Chow, E., Ma, R. C. W., Chan, J. C. N., & Luk, A. O. Y. (2026). Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70126

Vancouver

Fan Y, Fan B, Lau ESH, Lim CKP, Wu H, Chow EWK, et al. Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70126

BibTeX
@article{Fan2026,
  author = {Fan, Yingnan and Fan, Baoqi and Lau, Eric S H and Lim, Cadmon K P and Wu, Hongjiang and Chow, Edith W K and Kong, Alice P S and Chow, Elaine and Ma, Ronald C W and Chan, Juliana C N and Luk, Andrea O Y},
  title = {Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  doi = {10.1002/dmrr.70126}
}
Kostenlos starten →